Trial Search Results

Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants

This large multicenter double-masked clinical trial tested whether supplementation of standard neonatal parenteral nutrition with glutamine would reduce the risk of death or late-onset sepsis in extremely-low-birth-weight (ELBW, less than or equal to 1000 gm) infants. Neonates with birth weights of 401-1000gm were randomized to standard TrophAmine or TrophAmine supplemented with glutamine before 72 hours and continued until the infants are tolerating full enteral feedings.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

NICHD Neonatal Research Network

Collaborator: National Center for Research Resources (NCRR)

Stanford Investigator(s):

Intervention(s):

  • Drug: Glutamine
  • Drug: Placebo

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - 401-1000 gm

   - More than 12 hrs and less than 72 hrs after birth; intravenous access

   - Parental consent

Exclusion Criteria:

   - One or more major congenital anomalies

   - Infants meeting criteria for terminal illness

   - Congenital nonbacterial infection with overt signs at birth

Ages Eligible for Study

N/A - 72 Hours

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting